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Expression of viral proteins causes important epigenetic
changes leading to abnormal cell growth. Whether viral
proteins directly target histone methyltransferases
(HMTs), a key family enzyme for epigenetic regulation,
and modulate their enzymatic activities remains elusive.
Here we show that the E6 proteins of both low-risk and
high-risk human papillomavirus (HPV) interact with three
coactivator HMTs, CARM1, PRMT1 and SET7, and
downregulate their enzymatic activities in vitro and in
HPV-transformed HeLa cells. Furthermore, these three
HMTs are required for E6 to attenuate p53 transactiva-
tion function. Mechanistically, E6 hampers CARM1- and
PRMT1-catalyzed histone methylation at p53-responsive
promoters, and suppresses the binding of p53 to chroma-
tinized DNA independently of E6-mediated p53 degrada-
tion. p53 pre-methylated at lysine-372 (p53K372 mono-
methylation) by SET7 protects p53 from E6-induced
degradation. Consistently, E6 downregulates p53K372
mono-methylation and thus reduces p53 protein stability.
As a result of the E6-mediated inhibition of HMT activity,
expression of p53 downstream genes is suppressed.
Together, our results not only reveal a clever approach
for the virus to interfere with p53 function, but also
demonstrate the modulation of HMT activity as a novel
mechanism of epigenetic regulation by a viral oncoprotein.
Oncogene (2012) 31, 2335–2349; doi:10.1038/onc.2011.415;
published online 3 October 2011
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Introduction
Human papillomaviruses (HPVs) cause cervical carci-
noma and are associated with several other human
cancers such as lung cancer (Chen et al., 2004; Ganguly
and Parihar, 2009). They are small viruses with a double-
stranded circular DNA, which replicates in the nucleus of
infected cells. Among the HPV proteins, the early proteins
E6 and E7 attract most attention as they transform and
immortalize cells (Ganguly and Parihar, 2009; McLaugh-
lin-Drubin and Munger, 2009). One of the well-docu-
mented mechanisms by which HPV causes cervical
carcinoma is E6-mediated degradation of the tumor
suppressor p53 (Scheffner et al., 1990; Munger and
Howley, 2002; Howley and Livingston, 2009). E6,
complexed with the E6-associated protein (E6AP), func-
tions as a ubiquitin ligase to perform p53 ubiquitination
for destruction (Scheffner et al., 1990; Scheffner et al.,
1993). Nevertheless, this is unlikely the only mechanism
by which E6 transforms cells. Additional p53-independent
functions/targets of E6 have been described (Howley,
2006; Howie et al., 2009). Several groups reported that
E6 inhibits the histone acetyltransferase activity of the
important coactivator p300 (Patel et al., 1999; Zimmer-
mann et al., 1999; Thomas and Chiang, 2005).
To activate gene transcription from the condensed
chromatin with DNA wrapped by histone and non-
histone chromosomal proteins, transcriptional activa-
tors with sequence-speciﬁc DNA-binding activity will
recruit coactivators to the regulatory sequence of a
particular gene. These coactivators usually contain at
least one of the following activities: as a scaffold protein,
histone modiﬁcation, ATP-dependent chromatin remo-
deling or the activity to regulate DNA methylation
(Trojer and Reinberg, 2007). Histone modiﬁers can
post-translationally modify histones as well as a growing
list of non-histone proteins (Lee and Stallcup, 2009;
Pradhan et al., 2009). The modiﬁcations on histones,
alone or in combination, constitute an epigenetic
language, which is believed to alter gene expression by
changing the DNA–histone interaction, histone–protein
interaction or by serving as signals to recruit other
regulators (Strahl and Allis, 2000).
Many sites on histone tails can be modiﬁed by various
histone modiﬁers. Up to date, the reported modiﬁca-
tions include acetylation, methylation, phosphorylation,
ubiquitination, sumoylation, ADP-ribosylation, proline
isomerization, and so on (Kouzarides, 2007; Campos
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www.nature.com/oncand Reinberg, 2009). Unlike histone acetylation, a
hallmark of gene activation occurring exclusively on
lysine, histone methylation is involved in both gene
activation and repression, and takes place on both lysine
and arginine. Arginine could be di-methylated either
asymmetrically by type-I arginine histone methyltrans-
ferases (HMTs) or symmetrically by type-II HMTs
(Wolf, 2009). An et al. (2004) showed that p53 recruits
the type-I arginine HMTs CARM1 and PRMT1 to
methylate histones at p53-responsive promoters and
activate p53 downstream genes. Notably, CARM1 and
PRMT1 coactivate and methylate many other proteins
(Lee and Stallcup, 2009). By contrast, lysine can be
mono-, di- or tri-methylated (Shukla et al., 2009). SET7
performs mono-methylation on lysine-4 of H3 to exert
its coactivation function (Wang et al., 2001; Nishioka
et al., 2002). Likewise, SET7 methylates non-histone
substrates, which include p53 (Pradhan et al., 2009).
SET7-mediated mono-methylation of p53 at K372
(p53K372me1) increases p53 stability, likely through
recruitment of the histone acetyltransferase Tip60 for
p53 acetylation (Kurash et al., 2008). SET7-mediated
p53 methylation also antagonizes the transcriptional
repression by Smyd2-mediated p53 methylation (Huang
et al., 2006).
Whether functions of HMTs can be modulated by
viral proteins remains mysterious. In the current study,
we take p53, a well-known target of E6, as an example
to illustrate how E6 modulates the activities of HMTs
CARM1, PRMT1 and SET7 for controlling
gene-speciﬁc transcription. We found that E6 at the
physiological concentration downregulated p53 tran-
scriptional activity and stability through inhibition of
the arginine-speciﬁc HMTs CARM1 and PRMT1, and
the lysine-speciﬁc HMT SET7. As these HMTs are
important coactivators and enzymes not only for p53,
the study strongly suggests that the oncogenic function
of E6 is contributed by more factors than previously
appreciated. Our study provides the ﬁrst evidence
to show HMT inhibition by a viral oncoprotein.
Results
E6 interacts with endogenous CARM1, PRMT1
and SET7 in cells
To investigate whether E6 functions through modula-
tion of HMTs, CARM1, PRMT1 and SET7 were
analyzed as these HMTs facilitate the function of p53,
a well-known target of E6 (An et al., 2004; Chuikov
et al., 2004). First we asked whether E6 interacts with
these HMTs in cells. The high-risk HPV type-18 E6
(18E6)-expressing cervical carcinoma cell HeLa was
harvested and subjected to immunoprecipitation (IP)
using IgG or antibody (Ab) against 18E6, followed
by western blotting with Ab against CARM1, PRMT1
or SET7. As shown in Figure 1a, the E6 Ab only
co-immunoprecipitated CARM1, PRMT1 and SET7 in
HeLa cells with a scramble RNA, but failed to do so
when 18E6 was knocked down by si-18E6 (compare lane
6 with lane 5, lane 12 with lane 11, and lane 18 with lane
17). Note that depleting 18E6 from HeLa cells only
increased the p53 protein level, but did not affect the
level of CARM1, PRMT1 or SET7 (Figure 1 and
Supplementary Figure S1). Next we investigated
whether E6 of the low-risk HPV type-11 (11E6) is also
capable of binding to these HMTs. To do so, U2OS cells
ectopically expressing Flag-tagged 11E6 or 18E6 were
subjected to IP and western blot analysis. Figure 1b
shows that CARM1, PRMT1 and SET7 Abs pulled
down both Flag-11E6 and Flag-18E6, but not actin.
These results indicate that both high- and low-risk HPV
E6 speciﬁcally associate with endogenous CARM1,
PRMT1 and SET7.
E6 inhibits the methyltransferase activity of CARM1,
PRMT1 and SET7 in vitro
In vitro methyltransferase assays were then applied to
test whether E6 directly affects the enzymatic activities
of CARM1, PRMT1 and SET7. To this end,
western blotting using Ab against CARM1-mediated
asymmetric di-methylation of histone H3 at R17
(Asy-H3R17me2) or PRMT1-induced asymmetric di-
methylation of H4 at R3 (Asy-H4R3me2) was per-
formed. As shown in Figures 2a and b, CARM1 and
PRMT1 methylated histones H3 and H4, respectively
(compare lane 2 with lane 1). Increasing amounts of
11E6, 16E6 (E6 of high-risk HPV 16) or 18E6 markedly
reduced histone methylation in an E6 dose-dependent
manner (lanes 3–8). As control, glutathione-S-transfer-
ase did not affect CARM1- or PRMT1-mediated
histone methylation (lane 9). The phenomenon was
further conﬁrmed by using a radiolabeled methionine
donor (Supplementary Figures S2A and B). Similar
results were obtained when SET7 was examined on
histones (Supplementary Figure S2C) or p53 was used as
the substrate for SET7 (Figure 2c). Note that neither
CARM1 nor PRMT1 methylated p53 (data not shown).
Stoichiometry analysis of the proteins included in the
above in vitro methyltransferase assays (shown as molar
rations in the ﬁgure legends) indicates that less
than three-fold molar excess of E6 to HMT greatly
downregulated HMT function. These results show that
E6 directly inhibits HMT activity.
E6 inhibits CARM1- and PRMT1-mediated p53
transactivation function in a p53 degradation-
independent manner
As E6 interacted with CARM1, PRMT1 and SET7
(Figure 1), and directly downregulated their enzymatic
activities (Figure 2), it is expected that gene transcrip-
tion modulated through this pathway is affected. To test
this possibility, we used the p53-target gene p21 as an
example. As expected, exogenous expression of p53 in
p53-null H1299 cells increased the activity of the
luciferase reporter driven by the p21 promoter
(Figure 3a, column 2), which was further boosted by
CARM1 or PRMT1, or both (columns 3–5). In the
presence of 18E6, the transactivation function of p53
was reduced (compare column 7 with column 2),
presumably because of the degradation of a certain
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Oncogeneportion of p53 (western blot in Supplementary Figure
S3, compare lane 4 with lane 3). Interestingly, neither
CARM1 nor PRMT1 further enhanced the transcrip-
tional activity of the remaining p53 under this condition
(Figure 3a, compare columns 8, 9 and 10 with column
7). As the protein levels of CARM1 and PRMT1 were
same regardless of the presence of E6 (Supplementary
Figure S3, compare lane 6 with lane 5, lane 8 with lane 7,
and lane 10 with lane 9), the result indicates that the
coactivation function of both CARM1 and PRMT1 was
abolished by E6. The reverse transcription (RT)–PCR
experiment in Figure 3b further conﬁrms that (i) the
endogenous p21 mRNA level in H1299 cells was
stimulated by p53, CARM1 and PRMT1 (compare
column 1 with column 3); (ii) E6-mediated p53
degradation resulted in a great loss of p21 mRNA level
(compare column 4 with column 2) and (iii) in the
presence of E6, the exogenous CARM1 and PRMT1 no
longer coactivated the remaining p53 in stimulating p21
mRNA synthesis (compare column 5 with column 4).
To further demonstrate that E6 is able to inhibit
p53-target gene expression through HMT inhibition but
not p53 degradation, an experiment similar to Figure 3a
was conducted, with H1299 treated with the proteasome
inhibitor MG132 to ensure that the p53 protein level is
equal regardless of the presence of E6. Consistently, E6
still suppressed the HMT-stimulated p53 activity under
this condition (Supplementary Figure S4, compare
columns 6, 8 and 10 with columns 5, 7 and 9), indicating
that HMT inhibition likely contributes to E6-mediated
downregulation of p53 downstream gene expression.
The hypothesis was further supported by using a
16E6-6C/6S/F47R mutant or 11E6, both of which
cannot induce p53 degradation (Crook et al., 1991;
Nomine et al., 2006). As shown in Figure 3c, these two
E6 were still capable of inhibiting p53-dependent p21
mRNA synthesis in H1299 treated with Adriamycin
(Adr), a DNA damage inducer known to stimulate
p53 activity (Tewey et al., 1984). Similar results were
obtained in U2OS cells (Supplementary Figure S5).
Using a short interfering RNA (siRNA) against
CARM1 or PRMT1, we further show that the
E6-mediated reduction of Adr-stimulated p21 mRNA
level was partly relieved upon knockdown of CARM1
and PRMT1 (Figure 3d, columns 1–4). As control, a
scramble RNA did not release the E6-dependent
reduction of p21 mRNA level (Figure 3d, columns
5–8). The data also indicated that, in the absence of E6,
depleting CARM1 and PRMT1 reduced Adr-mediated
p21 expression (Supplementary Figure S6, compare
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Figure 1 In vivo interaction of E6 and HMTs. HeLa cells (a) or E6-transfected U2OS cells (b) were harvested for IP with anti-18E6,
anti-CARM1, anti-PRMT1, anti-SET7 or IgG, followed by western blotting using Ab against the indicated proteins. The asterisk
indicates the immunoprecipitated HMTs in panel a. The input control represents 5% (a) or 10% (b) volume of cell lysates used for IP.
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Oncogenecolumn 4 with column 2), indicating that both HMTs
are essential in coactivating p53 function in vivo. These
data together argue that inhibition of endogenous
CARM1 and PRMT1 might contribute to the E6-
mediated repression of p53 function. Consistent results
were obtained from HeLa cells, which stably express
18E6. As shown in Figure 3e, Adr and exogenous
CARM1/PRMT1 signiﬁcantly enhanced endogenous
p21 mRNA expression only in cells depleted with
18E6 (lanes 7–9). The effect was not observed in mock
or scramble RNA-transfected HeLa cells (lanes 1–6).
These studies demonstrate that E6 at the physiological
level is sufﬁcient to inhibit CARM1- and PRMT1-
stimulated p53 function.
E6 suppresses CARM1- and PRMT1-mediated histone
methylation on p53-responsive promoters in cells
Given that E6 was demonstrated to inhibit CARM1-
and PRMT1-mediated p53 transactivation on p21 gene
expression (Figure 3), we continued to investigate if E6
suppresses the corresponding histone methylation at
p53-responsive promoters. To this end, the levels of
Asy-H3R17me2 and Asy-H4R3me2 known to be
mediated by CARM1 and PRMT1, respectively, were
analyzed in U2OS cells transiently expressing hemag-
glutinin (HA)-tagged wild-type (wt) or catalytically dead
CARM1 or PRMT1 with or without E6. As observed,
only low levels of histone methylation and acetylation
were detected without overexpressing HMTs (Figure 4a,
lane 1). Adding wt CARM1 or PRMT1, alone or
together, increased the levels of Asy-H3R17me2 and
Asy-H4R3me2, respectively, H4 acetylation and p53
binding to chromatin (lanes 2–4). By contrast, the
catalytic mutant of CARM1 or PRMT1 failed to induce
the same effect (lanes 5 and 6), indicating that the
CARM1- and PRMT1-catalyzed histone modiﬁcations
were critical for binding of p53 to chromatin. These
experiments demonstrate for the ﬁrst time that the
enzymatic activities of these two HMTs were important
for binding of p53 to its target promoters in vivo.
Importantly, in the presence of MG132 (lanes 7–9),
18E6 repressed the CARM1- and PRMT1-stimulated
histone methylation and acetylation, as well as p53
binding (compare lane 9 with lane 8). Quantiﬁcation of
these chromatin IP (ChIP) results by real-time PCR is
shown in Supplementary Figure S7. The western blots
below the ChIP results (Figure 4a, bottom panel) further
conﬁrm that the above effects were not due to variation
of the protein levels of p53, CARM1 and PRMT1.
Subsequently we examined whether E6 downregulates
the histone methylation caused by endogenous CARM1
and PRMT1. In the presence of MG132 and Adr, U2OS
cells with or without 18E6 were subjected to ChIP
assays. Similarly, expression of E6 suppressed Asy-
H4R3me2 and Asy-H3R17me2 on the promoters of p21
and another p53-target gene, GADD45. Only the p53-
binding region, but not on the distal p53-unrelated
region, was affected (Supplementary Figure S8). As
control, the western blot shows that, in the presence of
MG132, the p53 level was unchanged with or without
E6 (bottom panel). Thus, E6 downregulates endogenous
CARM1 and PRMT1 activities on p53-target genes.
Whether the HMT- and E6-mediated alteration of
histone modiﬁcation on p21 and GADD45 genes was
indeed through p53 was analyzed. The ChIP assays
shown in Figure 4b indicate that ectopically expressed
p53 bound to both p21 and GADD45 promoters in
H1299 cells. p53 recruited CARM1 and PRMT1 to the
p21 and GADD45 promoters, and enhanced the
corresponding histone methylation as well as histone
acetylation. As observed, all these effects were abolished
in the presence of 18E6 (lanes 3 and 6). As a negative
control, symmetric di-methylation of H3R26 (Sym-
H3R26me2), a mark mediated by neither CARM1 nor
PRMT1, was unaffected by expression of p53 or E6.
Again, the western blot results show no decrease of p53
protein level by E6 in the presence of MG132 (compare
lane 9 with lane 8).
Furthermore, we showed that depleting E6 from
HeLa cells enhanced Asy-H4R3me2, Asy-H3R17me2
and H4 acetylation on both p21 and GADD45
promoters (Figure 4c), indicating that E6 at the
physiological level suppresses endogenous CARM1-
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Figure 2 In vitro inhibition of HMT activities by E6. E6 inhibits
the methyltransferase activities of CRAM1 (a), PRMT1 (b) and
SET7 (c). (a, b) The indicated proteins (2mg of each HMT, 1 or 2mg
of each E6, and 10mg of core histone proteins) were mixed with
SAM. The reaction products were separated by 15% SDS–PAGE.
The gels were analyzed by western blotting using Abs against H3
asymmetrically di-methylated at R17 (Asy-H3R17me2) and histone
H3 in panel a or H4 asymmetrically di-methylated at R3 (Asy-
H4R3me2) and histone H4 in panel b. The molar ratios of histone
H3 to CARM1 to E6 are 1:0.2:0.37 (lanes 3, 5 and 7) and 1:0.2:0.72
(lanes 4, 6 and 8) in panel a, and of histone H4 to PRMT1 to E6 are
1:0.21:0.24 (lanes 3, 5 and 7) and 1:0.21:0.48 (lanes 4, 6 and 8) in
panel b.( c) The indicated proteins (2mg of each HMTs, 2 or 5mgo f
each E6, and 5mg of p53) were mixed with [
3H]-SAM (S-adenosyl-
L-[methyl-
3H]-methionine). The reaction products were separated
by 15% SDS–PAGE. The gels were stained with Coomassie
blue (upper panel) and analyzed by phosphoimaging (lower panel).
The molar ratios of p53 to SET7 to E6 are 1:0.44:1.18 (lanes 3, 5
and 7) and 1:0.44:2.94 (lanes 4, 6 and 8).
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Oncogeneand PRMT1-mediated histone methylation on p53-
responsive promoters. Similar to 18E6, 11E6, which
does not degrade p53, also repressed CARM1
and PRMT1 activities on p53-responsive promoters
(Figure 5). Collectively, these results suggest that both
high-risk and low-risk E6 are capable of downregulating
p53-dependent promoter activity through suppression of
HMT function in vivo.
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Figure 3 E6 inhibits the CARM1- and PRMT1-stimulated p53-dependent transcription. (a) CARM1 and PRTM1 fail to stimulate
the p53 transactivation function in the presence of E6. (b) E6 suppresses CARM1- and PRMT1-induced p21 expression. (a, b) H1299
cells were transfected with the indicated plasmids, followed by luciferase assay (a), RT–PCR and western blot analysis (b). (c) 11E6 and
16E66C/6S F47R do not interfere with p53 protein level but inhibit p21 expression. H1299 cells were transfected with the indicated
plasmids for 48h and then treated with Adr for another 6h, followed by RT–PCR and western blot analysis. (d) Knocking down
CARM1 and PRMT1 relieves the E6-mediated inhibition of endogenous p21 expression. After 24h of siRNA transfection, U2OS cells
were transfected with a plasmid encoding E6 for another 48h. (e) Deletion of E6 from HeLa cells restores CARM1- and PRMT1-
enhanced p21 expression. After 24h of siRNA transfection, HeLa cells were transfected with plasmids encoding CARM1 and PRMT1
for 48h, or treated with Adr for 6h. (d, e) After transfection, quantitative RT–PCR and western blotting were performed. sc-RNA
indicates si-scramble control.
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Figure 4 E6 represses CRAM1 and PRMT1 activity-dependent p53 binding and histone modiﬁcations on p53-responsive promoters.
U2OS cells transfected with the indicated expression vectors in the absence (lanes 1–6) or presence (lanes 7–9) of MG132 (a) and H1299
cells transfected with the indicated expression vectors in the presence of MG132 (b) were subjected to ChIP assays on the p21 or the
GADD45 promoter, and western blotting was performed by using Abs against the indicated proteins. (c) HeLa cells treated with Adr
and MG132 in the presence of scramble RNA (open square) or si-18E6 (ﬁlled square) were subjected to ChIP using Abs against the
indicated proteins.
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OncogeneE6 represses p53 binding to chromatinized DNA by
interacting with p53
The ChIP experiments in Figure 4 have identiﬁed that
18E6 binding to p53-target gene promoters accompa-
nied the loss of p53 binding. To further conﬁrm this
phenomenon, ChIP and DNA afﬁnity protein assay
(DAPA) were applied in H1299 cells, with exogenously
added p53. The ChIP assay indicates that 18E6 alone,
even at a high concentration, failed to bind to the p21 or
the GADD45 promoter (Figure 6a, lane 1). Association
of E6 with both p21 and GADD45 promoters was only
observed when p53 was present (lane 3), indicating that
E6 targets p53-responsive promoters by interacting with
p53. Interestingly, binding of p53 and E6 were both
diminished when more E6 was added (lane 4). Quanti-
ﬁcation of the results by real-time PCR is shown in
Supplementary Figure S9.
We hypothesized that the E6-reduced p53 binding to
chromatin was a result of alteration in histone
modiﬁcation, but not due to a conformational change
in p53 that impairs the binding of p53 to free DNA.
The idea was conﬁrmed by the following DAPA assay.
A biotin-labeled DNA fragment containing the p53-
binding element of the p21 promoter or a random
sequence (Figure 6b, illustration at the top) was linked
to streptavidin beads and incubated with H1299 cell
lysates under the same transfection conditions as in
Figure 6a. p53 was precipitated by beads containing the
p53-binding element of the p21 promoter, but not by
beads conjugated with a random probe, indicating that
p53 only binds to a speciﬁc DNA fragment (lane 3).
Whereas E6 alone did not associate with the p53-
binding element or the random sequence (lane 2), it
bound to the p53-responsive element when p53 was
expressed in cells (lanes 4 and 5). As a negative control,
b-tubulin could not be precipitated by the p21 probe,
suggesting that E6 recruitment by p53 to the p53-
binding element was speciﬁc. Importantly, E6 did not
interfere with the DNA-binding ability of p53 (compare
lanes 4 and 5 with lane 3). A similar DAPA result was
obtained by using a 214-bp DNA fragment containing
the same sequence and length as that examined by the
ChIP in Figure 6a (Supplementary Figure S10A). Note
that, although the 214-bp DNA fragment theoretically
could hold a nucleosome, which occupies approximately
146bp, the DNA was unlikely assembled into the
nucleosome-like structure as successful reconstitution
of chromatin requires additional chromatin assembly
factors/histone chaperons, which were not included
in this case. To further conﬁrm this, we show that the
214-bp probe in the DAPA condition failed to pull
down histone H3 (Supplementary Figure S10B). Thus, it
is concluded that E6 only affects p53 binding to histone-
bound DNA, but not free DNA, consistent with the idea
that histone methylation determines the binding of p53
to chromatin (Figure 4a).
We continue to investigate whether E6 represses p53
binding to chromatin in HeLa cells. As shown in
Figure 6c, both MG132 treatment and E6 depletion
increased the p53 protein level (compare lanes 2 and
3 with lane 1). Nevertheless, p53 binding to p21
promoter was largely increased only in cells deﬁcient
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Figure 5 Low-risk HPV type-11 E6 downregulates CARM1 and PRMT1 activities in vivo.( a) 11E6 represses the CARM1- and
PRMT1-induced GADD45 mRNA level and the corresponding histone modiﬁcations on the GADD45 promoter. U2OS cells
ectopically expressing HA-CARM1 and HA-PRMT1 with or without 11E6 were subjected to RT–PCR, western blotting and ChIP
assays. As shown, overexpression of CARM1 and PRMT1 increased the GADD45 mRNA level (compare lane 2 with lane 1) as well as
the corresponding histone modiﬁcations on the GADD45 promoter (compare lane 5 with lane 4). In the presence of 11E6, all these
CARM1- and PRMT1-stimulated effects were attenuated (compare lane 3 with lane 2 and lane 6 with lane 5), indicating that 11E6,
which does not degrade p53 (as seen in the western blotting), could antagonize the CARM1- and PRMT1-mediated expression of the
p53-target gene. (b) 11E6 downregulates the Adr-induced GADD45 mRNA level and the corresponding histone methylation and
acetylation on the GADD45 promoter. U2OS cells with or without 11E6 and Adr were subjected to RT–PCR for GADD45 mRNA
analysis and ChIP assays using Ab against Asy-H4R3me2 or Ace-H4.
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Oncogenein E6 (compare lane 3 with lane 2), indicating that the
stably expressed E6 is sufﬁcient and necessary to repress
p53 binding to its target promoter. In HeLa cells, we
also showed that knockdown of p53 not only reduced
the chromatin-bound p53, but also diminished E6
binding to the same promoter region (Figure 6d),
further supporting our hypothesis that E6 targets
p53-resposive promoters by associating with p53.
E6 downregulates p53 stability by inhibiting
SET7-catalyzed p53 methylation
So far our data demonstrate that the E6-mediated
downregulation of the HMT activities of CARM1 and
PRMT1 has important function in vivo. Whether
inhibition of SET7 by E6 observed in vitro (Figure 2)
is also physiologically relevant was investigated. Again,
p53 was used as a working model as p53 is one of the
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Figure 6 E6 inhibits p53 binding to chromatin. H1299 cells were transfected with the indicated expression vectors and treated with
MG132 followed by ChIP (a, top and middle panels), western (a, bottom panel) and DAPA (b) assays. (a) E6 suppresses p53 binding to
endogenous p21 (upper panel) and GADD45 (middle panel) promoters. (b) E6 does not affect p53 binding to the non-chromatinized
DNA containing the p53-binding site of the p21 promoter. (c) Knocking down E6 increases p53 binding to the p21 promoter.
(d) Knocking down p53 reduces E6 binding to the p21 promoter. (c, d) HeLa cells were treated with MG132 or transfected with the
indicated siRNAs, followed by ChIP, RT–PCR and western blot analysis.
E6 inhibits distinct HMTs
C-H Hsu et al
2342
OncogeneSET7 substrates and E6 targets. First we conﬁrmed
whether SET7, and presumably the resulting mono-
methylation of p53 at lysine-372 (p53K372me1), stabi-
lizes p53 protein level as reported earlier (Chuikov et al.,
2004; Ivanov et al., 2007; Kurash et al., 2008). As
observed in Supplementary Figure S11, without Adr
treatment, knocking down SET7 (lane 3) or expressing
methylase-dead SET7 (lane 4) affected neither p53 nor
p21 protein level in U2OS cells, indicating that SET7
unlikely controls p53 stability and activity under normal
conditions. By contrast, Adr induced p53 and p21 levels
(compare lane 5 with lane 1), but failed to do so when
SET7 was knocked down (lane 7) or the catalytically
dead SET7 was included (lane 8), indicating that SET7
activity on p53 (p53K372me1) is required for p53
stabilization and downstream gene expression in
response to genotoxic stresses. Subsequently, we in-
vestigated whether SET7 indeed contributes to the
E6-mdiated repression of p53 function under DNA
damage conditions. As shown in Figure 7a, the 16E6-
mediated inhibition of p21 expression (compare lane 2
with lane 1) was greatly lost when SET7 was depleted
from U2OS cells (compare lane 4 with lane 3), indicating
that E6-mediated repression of p53 function depends on
SET7. Consistently, E6 reduced SET7-mediated p53
methylation in DNA damage-induced cells. As shown in
Figure 7b, p53K372me1 signal was abolished in U2OS
cells expressing Flag-18E6 (lanes 1 and 2) and stimu-
lated in HeLa cells depleted of 18E6 (lanes 3 and 4). p21
protein level was induced as well in HeLa cells without
18E6 (lane 4). We further addressed that SET7 was
required to maintain Adr-induced p53 protein level in
both U2OS and HeLa cells as p53 protein level
decreased upon SET7 knockdown (Figure 7c, lanes 3
and 6). As expected, Adr only slightly enhanced the p53
level in HeLa cells, compared with that in U2OS cells
(compare lane 5 with lane 2). SET7 depletion almost
totally abolished the p53 protein level in HeLa cells
(compare lane 6 with lane 4), whereas a certain portion
of p53 was left upon SET7 depletion in U2OS cells
(compare lane 3 with lane 1). These differential effects
are likely due to the stable E6 expression in HeLa cells.
In agreement with this idea, E6 knockdown in HeLa
cells greatly recovered the p53 protein level (compare
lane 7 with lane 5). These in vivo results strongly suggest
that endogenous SET7 protects p53 from E6-mediated
p53 degradation.
An IP-coupled degradation assay was next used to
address whether p53 mono-methylated at K372 is
preferentially protected from E6-mediated degradation.
As shown in Figure 7d, equal amounts of p53 from
U2OS cells with or without Adr treatment were
immunoprecipitated with Ab against p53K372me1
(lanes 1 and 2) or Ab against total p53, and then
subjected to E6-mediated in vitro degradation assays
(lanes 3 and 4) (see section Materials and methods). p53
from cells stimulated with Adr was preferentially mono-
methylated at K372 (compare lane 2 with lane 1) and
prevented from degradation (compare lane 4 with
lane 3), indicating that E6 preferentially degrades the
endogenous p53 unmethylated by SET7.
The interrelationship between E6-dependent SET7
inhibition and E6-mediated p53 degradation was
further clariﬁed with a more puriﬁed system, the
in vitro transcription–translation-coupled degradation
assay. p53, SET7 and E6 were in vitro transcribed and
translated from rabbit reticular lysate, mixed in different
combination with the methyl group donor S-adenosyl-L-
methionine (SAM) and incubated as illustrated in
Figure 7e. The protein levels of p53 at Stage 1 show
equal input. E6 reduced the protein level of p53,
presumably unmethylated in the reaction lysates (com-
pare lane 2 with lane 1). Interestingly, the p53 protein
level was partly recovered when the reaction mixture
also contained both exogenous SET7 and SAM (lane 5).
SAM or SET7 alone did not prevent the E6-mediated
p53 reduction (lanes 3 and 4). These data support our
hypothesis that the methyltransferase activity of SET7
protects p53 from E6-mediated degradation. We con-
tinued to investigate whether p53 pre-methylated by
SET7 resists E6-mediated degradation. To this end, we
examined whether SAM added later than E6 fails to
work with SET7 to prevent p53 from degradation by E6.
The in vitro transcribed and translated p53 and SET7
were mixed at Stage 1, followed by incubation with E6
at Stage 2. SAM was added at Stage 1 or Stage 2.
As shown in Figure 7f, the p53 protein level remained
unchanged at all conditions at Stage 1 or Stage 2.
Remarkably, only SAM added at Stage 1 successfully
protected p53 from E6-mediated degradation, as deter-
mined by the p53 protein level at the stop stage (lane 3).
By contrast, SAM added at Stage 2 failed to work with
SET7 to recover the p53 protein level (lane 6). These
data indicate that E6 only degrades p53, which is not
previously methylated by SET7. To further support this
notion, we examined the effect of E6 on the p53K372R
mutant, which lacks the residue to be methylated by
SET7. SET7, SAM, p53K372R and E6 were incubated
in the order illustrated in Figure 7g. Consistently, the
protein level of p53K372R was reduced by E6 (lane 2)
and could not be recovered by SET7 and SAM (lane 3).
The results strongly indicate that SET7 fails to
protect the methylation-site mutant p53K372R from
E6-mediated degradation. In other words, p53 requires
to be methylated by SET7 to escape from E6-mediated
degradation. Overall, these experiments demonstrate
that E6-mediated inhibition of SET7 activity is
upstream from E6-induced p53 degradation.
Discussion
The current work presents the ﬁrst evidence to show that
HPV E6 is able to suppress the activities of both the
arginine-speciﬁc HMTs, CARM1 and PRMT1, and the
lysine-speciﬁc HMT, SET7. The inhibition is function-
ally signiﬁcant in HPV-transformed cells as through this
E6 downregulates the stability and transactivation
function of p53. Figure 8 provides a model based on
our current ﬁndings and reports by others. In HPV-non-
infected normal cells (Figure 8a), DNA damage induces
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OncogeneSET7-mediated p53 methylation and stabilization
(Chuikov et al., 2004; Ivanov et al., 2007; Kurash
et al., 2008), as well as p53-dependent recruitment of
CARM1 and PRMT1 to p53-target gene promoters for
transcriptional activation (An et al., 2004). In HPV E6-
expressing cells (Figure 8b), E6 attenuates stress-induced
p53 function at least through the following two distinct
pathways: (1) E6 downregulates p53 protein stability
depending on E6AP (Scheffner et al., 1990, 1993) or by
inhibiting SET7-mediated p53 methylation at K372
(Figure 7). Given that p53 pre-methylated by SET7
resists E6-triggered degradation (Figure 7), inhibition of
SET7 by E6 might prime E6-mediated p53 degradation.
This also in part explains the fact that not all p53 is
degraded in E6-expressing cells (Howie et al., 2009);
(2) E6 can further target p53-responsive promoters
(Figure 6) and downregulate the corresponding histone
methylation mediated by the p53 coactivators CARM1
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Figure 7 E6 downregulates SET7-mediated p53 methylation and stability. (a) Knocking down SET7 relieves the E6-mediated
repression of p21 expression. U2OS cells transfected with 16E6 in the absence (lanes 1 and 2) or presence (lanes 3 and 4) of si-SET7
were treated with Adr for 6h, followed by RT–PCR for p21 mRNA level and western blotting. (b) E6 inhibits p53 methylation at K372
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not protect the p53K372R mutant from E6-mediated degradation. (e–g) Both p53 and 16E6 were in vitro transcribed and translated.
p53 was incubated with or without 16E6, puriﬁed SET7 or SAM in the order shown in the scheme, followed by western blotting to
show the p53 protein level at the indicated stage.
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Oncogeneand PRMT1 (Figure 4), leading to reduced binding of p53
to chromatin (Figures 4 and 6) and loss of p53
transactivation (Figure 3). Together, a novel model is
provided to show the dual roles of E6 in regulating p53
function through modulation of distinct HMT activity. We
not only demonstrate the upstream regulatory mechanism
leading to E6-mediated p53 degradation, but also reveal an
alternative approach for E6 to shut down the function of
the remaining p53 not degraded by E6. As CARM1,
PRMT1, and SET7 are critical co-regulators not only for
p53 (Lee and Stallcup, 2009; Pradhan et al., 2009) and E6
associates with these HMTs in p53-null H1299 cells
(Supplementary Figure S12), E6-mediated HMT inhibition
is expected to have a broader impact.
The remaining p53 escaping from E6-mediated
degradation is still active in transcription
As shown in Figure 3, the remaining p53 escaping from
E6-mediated degradation was still able to activate
transcription to 5.7-fold (compare lane 7 with lane 6).
Results published by two other laboratories also support
the same conclusion. First, Zimmermann et al. (1999)
showed that the remaining p53 still retained 1/3 of the
total p53 activity (Figure 7a in Zimmermann et al., 1999,
compare bar 4 with bar 2). Second, Patel et al. (1999)
demonstrated that the remaining p53 regained activity
in the presence of the histone acetyltransferase p300
(Figure 8a in Patel et al., 1999, compare bar 5 with
bar 4). Therefore, we believe that the remaining p53 is
still active in transcription.
Distinct roles of CARM1, PRMT1 and SET7 in
mediating p53 function
Although CARM1, PRMT1 and SET7 all interacted
with p53, unlike PRMT1 and CARM1, SET7 did not
enhance p53 transactivation function without DNA-
damage insult (compare Figure 3 with Supplementary
Figure S13). This is not surprising as SET7 activity is
minimal unless being induced by DNA damage (Ivanov
et al., 2007). In addition, only SET7 among these three
HMTs methylates p53 under stress (Chuikov et al.,
2004; Ivanov et al., 2007; Kurash et al., 2008; Figure 2,
and data not shown). In agreement with previous
reports (Chuikov et al., 2004; Ivanov et al., 2007;
Kurash et al., 2008), we found that the enzymatic
activity of SET7 was important for p53 stabilization and
downstream gene expression in response to DNA-
damage stress (Supplementary Figure S11). It is likely
that SET7 methylates p53 and directly prevents
p53 from being ubiquitylated as K372 is one of p53
ubiquitylation sites (Kruse and Gu, 2008). Alternatively,
p53 methylation by SET7 might indirectly inﬂuence p53
protein stability by facilitating p53 acetylation. Indeed,
SET7-mediated p53K372 methylation primes p53
acetylation on several sites in the C-terminus (Ivanov
et al., 2007; Kurash et al., 2008), and p53 acetylation
increases p53 stability by blocking the ubiquitination
sites of p53 (Li et al., 2002). These mechanisms likely
explain how p53 methylation by SET7 resists E6-
dependent p53 degradation through E6AP/ubiquitin
(Scheffner et al., 1990, 1993). Nevertheless, E6-triggered
p53 degradation can rely on neither E6AP (Massimi
et al., 2008) nor ubiquitin (Camus et al., 2007). Whether
E6-mediated SET7 inhibition also contributes to the
ubiquitin-independent pathway remains unknown.
Low-risk E6, which does not degrade p53, downregulates
p53 function through HMTs
Although low-risk HPVs have no detectable cell
transformation or immortalization activity, they are
major causative agents of anogenital warts and recur-
rent respiratory papillomatosis (Lacey et al., 2006;
Hu and Goldie, 2008; Pim and Banks, 2010). For example,
almost 100% of anogenital warts are caused by HPV
type-6 or type-11 (Pim and Banks, 2010). The mechan-
ism by which low-risk HPVs cause abnormal cell growth
is largely unknown. Consistent with the previous report
in which low-risk E6 is shown to affect p53 function
through inhibition of p300 (Thomas and Chiang, 2005)
or destabilization of TIP60 (Jha et al.,2 0 1 0 ) ,i nt h e
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Figure 8 A model: E6 downregulates p53 function through HMT
repression. (a) Previous reports indicate that, in HPV-non-infected
cells, DNA-damage stress induces SET7-mediated p53 methylation
and stabilization, as well as recruitment of p53 and its coactivators
CARM1 and PRMT1 to p53-regulated genes for gene activation.
(b) We demonstrate that, in HPV E6-expressing cells, in addition to
directly targeting p53 for degradation through the E6AP pathway,
E6 is able to inhibit SET7-mediated p53 methylation and thus
reduce p53 protein stability. E6 can also target chromatin-bound
p53 and repress the activities of the p53 coactivators CARM1 and
PRMT1, leading to reduction of local histone methylation, which,
likely, in turn dissociates p53 from chromatin. p53-dependent gene
transcription is thus downregulated.
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Oncogenecurrent study we further observe that, similar to the high-
risk HPV E6, the low-risk E6 from HPV type-11
suppressed p53 transactivation function likely by targeting
HMTs (Figures 2, 3c and 5, and Supplementary Figures
S2 and S5). This strongly suggests that both low-risk and
high-risk E6 proteins may induce abnormal cell growth by
interfering with the function of p53 and HMTs.
Global impact of E6-mediated HMT inhibition
Given that (i) E6 interacts with CARM1, PRMT1 and
SET7 regardless of the presence of p53 (Supplementary
Figure S12); (ii) E6 directly inhibits the enzymatic
activities of these HMTs (Figure 2); and (iii) these
HMTs are involved in a variety of cellular functions
by methylating a growing list of substrates, the p53-
independent impact of E6-mediated HMT inhibition is
expected. CARM1 and PRMT1 belong to the protein
arginine methyltransferase family, which at least con-
tains 10 members with homology within the active site
(Lee and Stallcup, 2009). They participate in various
cellular processes involved in signal transduction,
cell proliferation, transcriptional regulation, chromatin
remodeling, DNA repair, RNA processing, protein
stability and nucleo-cytoplasmic trafﬁcking (Pahlich
et al., 2006; Pal and Sif, 2007; Lee and Stallcup, 2009;
Wolf, 2009). Importantly, preventing PRMT1-mediated
methylation disturbs the DNA-repair function of
MRE11 and 53BP1 (Boisvert et al., 2005a,b). PRMT1
is also critical in maintaining genome integrity (Yu et al.,
2009). The lysine-speciﬁc HMT SET7 methylates a
list of non-histone proteins besides p53. These include
TAF10, p65 of nuclear factor-kB, DNA methyltrans-
ferase-1 (DNMT1) and estrogen receptor (ER) (Kous-
kouti et al., 2004; Subramanian et al., 2008; Ea and
Baltimore, 2009; Esteve et al., 2009; Yang et al., 2009).
SET7-mediated DNMT1 methylation decreases
DNMT1 protein stability (Esteve et al., 2009). Note
that defects in DNA repair and genome integrity are
signs for cancer, and that DNMT1 is generally induced
and stabilized in cancer cells to methylate the tumor-
suppressor gene promoter for subsequent transcrip-
tional suppression of the gene (Miremadi et al., 2007).
Thus, loss of CARM1, PRMT1 or SET7 function by E6
might contribute to the oncogenic activity of E6.
Viral regulation of histone methylation
Several viral mechanisms to affect gene transcription
involve modulation of histone methylation. These
include recruitment of G9a, Suv39h1 to the viral major
immediate-early promoter by the immediate-early-2
protein of the human cytomegalovirus (Reeves et al.,
2006); removal of the HMT-associated cellular tran-
scriptional regulator from DNA by adenovirus E1A
(Ghosh and Harter, 2003); recruitment of the histone
demethylase LSD1 by host cell factor-1 to immediate-
early promoters of herpes simplex virus and varicella
zoster virus (Liang et al., 2009); and direct expression of
viral protein with HMT activity such as the vSET
protein of paramecium bursaria chlorella virus-1
(Mujtaba et al., 2008). Together with our current study,
the importance of HMT regulation in viral survival is
highlighted.
Materials and methods
Cell line, DNA transfection and luciferase assay
The human cervix adenocarcinoma cell line, HeLa, the human
osteosarcoma cell line, U2OS, and the human lung carcinoma
cell line, H1299, were obtained from, and maintained as
instructed by, the ATCC (Manassas, VA, USA). DNA
transfections were performed by using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. For ectopic protein expression, cells were
harvested at 36B72h after transfection. For knockdown of
endogenous proteins, cells were collected 72h after transfec-
tion with 10nM speciﬁc siRNA (Ambion, Austin, TX, USA).
The sense sequence of si-SET7 is 50-GGACCGCACUUUA
UGGGAAtt-30;o fs i - C A R M 1i s5 0-AGACAGAGCUACGAC
AUCAtt-30;o fs i - P R M T 1i s5 0-GCAACUCCAUGUUUCAUA
Att-30; of si-18E6 is 50-GAAAAACUUAGACACCUUAtt-30;
and of si-p53 is 50-GUAAUCUACUGGGACGGAAtt-30.
Luciferase assays were performed as described previously (Juan
et al., 2000). Brieﬂy, transfections were performed at 80%
conﬂuence for H1299 and U2OS cells. Cells grown in six-well
dishes were harvested 48h after transfection. A 2- to 10-ml
volume of each lysate was mixed with 50ml of buffer (dual-
luciferase reporter assay system; Promega, Madison, WI, USA)
and measured for luciferase activities.
Plasmids
The following plasmids have been described previously:
pcDNA3-F16E6 (Patel et al., 1999; Thomas and Chiang,
2005) and p513-16E66C/6S F47R (Nomine et al., 2006), which
encode 16E66C/6S F47R and Flag-18E6, respectively; pcDNA
3.1-p53, which encodes wt p53 for mammalian expression (Ou
et al., 2005); pRL-SV40 (Dual-Luciferase Reporter Assay
System; Promega); p21-Luc (el-Deiry et al., 1993); pSG5HA-
CARM1, pSG5HA-PRMT1, pSG5HA-CARM1 E267Q and
pSG5HA-PRMT1 E153Q, encoding wt HA-CARM1,
HA-PRMT1 and their methylase-dead mutants, respectively
(Chen et al., 1999; Strahl et al., 2001; Lee et al., 2002, 2007);
and pcDNA3.1-SET7 and SET7 H297A, encoding, respec-
tively, wt SET7 and the methylase-dead mutant (Chuikov
et al., 2004). Plasmids pRK5-11E6 and pRK5-18E6, which
express Flag-HPV-11E6 and Flag-HPV-18E6, respectively,
were constructed by inserting the corresponding cDNA
fragments into the EcoRI and SalI sites of pRK5-Flag.
Plasmids pET-29a11E6, pET-29a16E6 and pET29a18E6,
which express His-tagged 11E6, 16E6 and 18E6, respectively,
in Escherichia coli were constructed by inserting the corre-
sponding cDNA fragments into the EcoRI and SalI sites of the
pET-29a(þ) vector (Novagen, Darmstadt, Germany). The
plasmid encoding the p53 point mutant p53K372R was
generated by using pcDNA 3.1-p53 as the template for
in vitro site-directed mutagenesis (Stratagene, Santa Clara,
CA, USA) according to the manufacturer’s instructions.
In vitro methyltransferase assay
A 10-mg weight of core histones (Millipore, Basel, Switzerland
or Roche, Basel, Switzerland) or a 5-mg weight of p53 made
from baculovirus (Wang et al., 2003) was mixed with
recombinant E6 protein puriﬁed from bacteria and recombi-
nant CARM1, PRMT1 or SET7 (Upstate, Billerica, MA,
USA, 14-575, 14-474 or 14-469, respectively), followed by
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adenosyl-L-[methyl-
3H]-methionine ([
3H]-SAM (1mCi/ml;
Amersham, Piscataway, NJ, USA) in HMT buffer (50mM
Tris–HCl (pH 8.0) and 0.5mM dithiothreitol). The reaction
mixtures were then separated by 15% sodium dodecyl sulfate
(SDS)–PAGE and the gels were stained with Coomassie blue,
dried and subjected to autoradiography. The non-isotope
methyltransferase assays were performed by using unlabeled
SAM to replace
3H-SAM. After in vitro methylation reaction,
proteins were separated by 15% SDS–PAGE, followed by
western blot analysis.
Western blotting, IP and DAPA
Cells were lysed on ice in ice-cold IP buffer (137mM NaCl,
2.7mM KCl, 7.7mM NaH2PO4, 1.5mM KH2PO4, 0.5% NP-40,
1m M EDTA, 10% glycerol, 1mM dithiothreitol) for IP or in
DAPA buffer (137mM NaCl, 2.7mM KCl, 7.7mM NaH2PO4,
1.5mM KH2PO4, 0.1% NP-40, 1mM EDTA, 10% glycerol,
1m M dithiothreitol) for DAPA. Both buffers contain a mixture
of protease inhibitors (Complete, EDTA-free, Protease In-
hibitor Cocktail Tablets; Roche Molecular Biochemicals,
Basel, Switzerland). Western blot and IP assays were
performed as described by Hsu et al. (2004). Brieﬂy, 4mg of
cell extracts from HeLa cells or 1mg from U2OS cells were
pre-cleaned with protein-A or protein-G beads for 30min, and
then incubated with the speciﬁc Ab at 41C overnight. Protein-
A or protein-G-conjugated beads were added for an additional
2h incubation. The beads were then collected by centrifugation
and washed six times with IP buffer. For DAPA, the
biotinylated DNA fragments were incubated with streptavidin
beads (S-1638; Sigma, St Louis, MO, USA) at 41C overnight
and washed three times with DAPA buffer. Subsequently, the
DNA-conjugated beads were incubated with 2mg of cell
lysates and 10mg of Poly dI–dC (Sigma; P4929) at 41C
overnight. The beads were then collected by centrifugation and
washed six times with DAPA buffer containing 0.5% NP-40.
The pulled down complexes were then resolved by 15% SDS–
PAGE and analyzed by western blotting.
Chromatin IP
ChIP assays were performed as described by Hsu et al. (2004),
with modiﬁcations. The immunoprecipitated DNA fragments
were extracted by using a PCR puriﬁcation kit (Qiagen,
Hilden, Germany; no. 28106) and analyzed by real-time PCR
(Light Cycler 480; Roche). The ampliﬁcations were performed
in a reaction volume of 20ml containing 2ml of immunopre-
cipitated material. The sequences of the p21 promoter-speciﬁc
primers are 50-GGCTGTGGCTCTGATTG-30 (forward) and
50-GAGGTCTCCTGTCTCCTAC-30 (reverse). The sequences
of the GADD45 promoter-speciﬁc primers are 50-TAGA
GTGTGGCTGGACTTT-30 (forward) and 50-TCACAGGG
ATCTCTTCCG-30 (reverse). The sequences of primers recog-
nizing the p53-unrelated region, approximately 2kb down-
stream from the p53-response element on the GADD45
promoter (An et al., 2004), are 50-GGAGTTGGAGTTGTCA
GGAAAAAGGG-30 (forward) and 50-GGTTGTGGTCTTT
CAGGCCTCCACACC-30 (reverse).
Antibodies
The commercial Abs used for western blotting were against the
following: b-tubulin (MAB1637; Millipore), actin (MAB1501;
Millipore), Flag (M2; Sigma), HA (MMS-101R; Covance,
Princeton, NJ, USA), CARM1 (A300-421A; Bethyl, Mon-
tgomery, TX, USA), PRMT1 (sc-13392; Santa Cruz, Santa
Cruz, CA, USA), SET7 (04-805; Millipore), histone H3
(ab1791; Abcam), Asy-H3R17me2 (07-214; Millipore), histone
H4 (ab10158), Asy-H4R3me2 (07-213; Millipore), p53 (DO-1)
(sc-126; Santa Cruz), p53K372me1 (ab16033; Abcam, Cam-
bridge, UK) and p21 (C-19; Santa Cruz). The commercial Abs
for IP and ChIP were against the following: CARM1 (A300-
421A; Bethyl, Figure 1a; and sc-5421; Santa Cruz, Figure 4b),
PRMT1 (sc-13392; Santa Cruz), SET7 (04-805; Millipore),
rabbit normal IgG (PP64B; Millipore), Ace-H3 (06-599;
Millipore), Asy-H3R17me2 (07-214; Millipore), Ace-H4 (06-
866; Millipore), Asy-H4R3me2 (07-213; Millipore), HPV E6
(sc-460 and sc-57835; Santa Cruz) and p53 (FL-393) (sc-6243;
Santa Cruz). The p53K372me1 Ab used in Figure 7d for IP
was generated by immunizing rabbits with the peptide NH2-
CSRAHSSHLKSK(me1)KG-COOH. The Abs against Asy-
H3R26me2 and Sym-H3R26me2 for IP were generated by
immunizing rabbits with KLH-conjugated NH2-KVAR(-
me2)KSAPC-COOH. The synthetic peptides corresponding
to the symmetric and asymmetric H3R26me2 were obtained
from Open Biosystems (Huntsville, AL, USA).
In vitro transcription/translation-coupled degradation assay
The assay was performed as described (Nomine et al., 2006) with
modiﬁcations. In vitro transcribed and translated proteins were
expressed form pcDNA3.1-SET7, pcDNA3-F16E6, pcDNA3.1-
p53, and pcDNA3.1-p53K372R by TNT system (Promega). p53
was then directly incubated with E6 in degradation buffer (25mM
Tris–HCl, pH 7.5, 100mM NaCl, 2mM dithiothreitol) at 281Cf o r
2h ,o rﬁ r s tw i t hS E T 7a n dS A Ma t3 0 1C for 30min and then E6.
Reactions were terminated by adding SDS sample buffer and
samples analyzed by western.
Reverse transcription–PCR
RNAs were extracted by using an RNA extraction kit (Qiagen;
no. 74134), reversed-transcribed and analyzed by real-time
RT–PCR (Light Cycler 480; Roche) using the QuantiTect
SYBR Green reagent (Qiagen; no. 204243). The expression
levels of the examined genes were normalized to actin
expression. The sequences of primers amplifying p21, GAD
D45, 18E6 and the b-actin gene are as follows: p21: 50-CTG
GAGACTCTCAGGGTCGAAA-30 (forward) and 50-GATT
AGGGCTTCCTCTTGGAGAA-30 (reverse); GADD45: 50-CCC
GGACCTGCACTGCG-30 (forward) and 50-TCAGATGCCAT-
CACCGT-30 (reverse); 18E6: 50-ATTAATAAGGTGCCTGCG
G-30 (forward) and 50-CTCTATAGTGCCCAGCTATGTT-30
(reverse); and b-actin: 50-CCCTGGACTTCGAGCAAGAGAT-
30 (forward) and 50-AAGGTAGTTTCGTGGATGCCACA-30
(reverse).
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